User menu

Assessment of panobacumab as adjunctive immunotherapy for the treatment of nosocomial Pseudomonas aeruginosa pneumonia

Bibliographic reference Que, Y.-A. ; Lazar, H. ; Wolff, M. ; François, B. ; Laterre, Pierre-François ; et. al. Assessment of panobacumab as adjunctive immunotherapy for the treatment of nosocomial Pseudomonas aeruginosa pneumonia. In: European Journal of Clinical Microbiology & Infectious Diseases : an international journal on pathogenesis, diagnosis, epidemiology, therapy, and prevention of infectious diseases, Vol. 33, no. 10, p. 1861-1867 (2014)
Permanent URL
  1. Eggimann Philippe, Pittet Didier, Infection Control in the ICU, 10.1378/chest.120.6.2059
  2. Vincent Jean-Louis, International Study of the Prevalence and Outcomes of Infection in Intensive Care Units, 10.1001/jama.2009.1754
  3. Tabah Alexis, Koulenti Despoina, Laupland Kevin, Misset Benoit, Valles Jordi, Bruzzi de Carvalho Frederico, Paiva José Artur, Çakar Nahit, Ma Xiaochun, Eggimann Philippe, Antonelli Massimo, Bonten Marc J. M., Csomos Akos, Krueger Wolfgang A., Mikstacki Adam, Lipman Jeffrey, Depuydt Pieter, Vesin Aurélien, Garrouste-Orgeas Maité, Zahar Jean-Ralph, Blot Stijn, Carlet Jean, Brun-Buisson Christian, Martin Claude, Rello Jordi, Dimopoulos Georges, Timsit Jean-François, Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT International Cohort Study, 10.1007/s00134-012-2695-9
  4. Harris Anthony D., Johnson J. Kristie, Thom Kerri A., Morgan Daniel J., McGregor Jessina C., Ajao Adebola O., Moore Anita C., Comer Angela C., Furuno Jon P., Risk Factors for Development of Intestinal Colonization with Imipenem-Resistant Pseudomonas aeruginosa in the Intensive Care Unit Setting, 10.1086/660763
  5. Ong David S. Y., Jongerden Irene P., Buiting Anton G., Leverstein-van Hall Maurine A., Speelberg Ben, Kesecioglu Jozef, Bonten Marc J. M., Antibiotic exposure and resistance development in Pseudomonas aeruginosa and Enterobacter species in intensive care units* : , 10.1097/ccm.0b013e318225756d
  6. Kollef Marin H., Silver Patricia, Murphy Denise M., Trovillion Ellen, The Effect of Late-Onset Ventilator-Associated Pneumonia in Determining Patient Mortality, 10.1378/chest.108.6.1655
  7. Trouillet J. L., Vuagnat A., Combes A., Kassis N., Chastre J., Gibert C., Pseudomonas aeruginosaVentilator‐Associated Pneumonia: Comparison of Episodes Due to Piperacillin‐Resistant versus Piperacillin‐Susceptible Organisms, 10.1086/339488
  8. Parker Chris M., Kutsogiannis Jim, Muscedere John, Cook Deborah, Dodek Peter, Day Andrew G., Heyland Daren K., Ventilator-associated pneumonia caused by multidrug-resistant organisms or Pseudomonas aeruginosa: Prevalence, incidence, risk factors, and outcomes, 10.1016/j.jcrc.2008.02.001
  9. Peña C., Gómez-Zorrilla S., Oriol I., Tubau F., Dominguez M. A., Pujol M., Ariza J., Impact of multidrug resistance on Pseudomonas aeruginosa ventilator-associated pneumonia outcome: predictors of early and crude mortality, 10.1007/s10096-012-1758-8
  10. Boucher HW, Talbot GH, Benjamin DK Jr, Bradley J, Guidos RJ, Jones RN, Murray BE, Bonomo RA, Gilbert D; Infectious Diseases Society of America (2013) 10 × ’20 Progress—development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis 56(12):1685–1694
  11. Chastre Jean, Luyt Charles‐Edouard, Other Therapeutic Modalities and Practices: Implications for Clinical Trials of Hospital‐Acquired or Ventilator‐Associated Pneumonia, 10.1086/653050
  12. François Bruno, Luyt Charles-Edouard, Dugard Anthony, Wolff Michel, Diehl Jean-Luc, Jaber Samir, Forel Jean-Marie, Garot Denis, Kipnis Eric, Mebazaa Alexandre, Misset Benoit, Andremont Antoine, Ploy Marie-Cécile, Jacobs Alan, Yarranton Geoffrey, Pearce Tillman, Fagon Jean-Yves, Chastre Jean, Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa : A randomized,double-blind, placebo-controlled trial*, 10.1097/ccm.0b013e31825334f6
  13. Hsu Jennifer L., Safdar Nasia, Polyclonal Immunoglobulins and Hyperimmune Globulins in Prevention and Management of Infectious Diseases, 10.1016/j.idc.2011.07.005
  14. Prophylactic Intravenous Administration of Standard Immune Globulin as Compared with Core-Lipopolysaccharide Immune Globulin in Patients at High Risk of Postsurgical Infection, 10.1056/nejm199207233270404
  15. Laupland Kevin B., Kirkpatrick Andrew W., Delaney Anthony, Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: A systematic review and meta-analysis* : , 10.1097/01.ccm.0000295312.13466.1c
  16. Abraham Edward, Cytokine Modifiers, 10.1378/chest.113.3_supplement.224s
  17. ter Meulen Jan, Monoclonal Antibodies in Infectious Diseases: Clinical Pipeline in 2011, 10.1016/j.idc.2011.07.006
  18. Rotschild M., Elias N., Berkowitz D., Pollak S., Shinawi M., Beck R., Bentur L., Autoantibodies against bactericidal/permeability–increasing protein (BPI–ANCA) in cystic fibrosis patients treated with azithromycin, 10.1007/s10238-005-0070-7
  19. Sawada S, Kawamura T, Masuho Y (1987) Immunoprotective human monoclonal antibodies against five major serotypes of Pseudomonas aeruginosa. J Gen Microbiol 133(12):3581–3590
  20. Lang Alois B., Schaad Urs B., Rüdeberg Anna, Wedgwood Joanna, Que John U., Fürer Emil, Cryz Stanley J., Effect of high-affinity anti-Pseudomonas aeruginosa lipopolysaccharide antibodies induced by immunization on the rate of Pseudomonas aeruginosa infection in patients with cystic fibrosis, 10.1016/s0022-3476(95)70158-3
  21. Hemachandra S., Kamboj K., Copfer J., Pier G., Green L. L., Schreiber J. R., Human Monoclonal Antibodies against Pseudomonas aeruginosa Lipopolysaccharide Derived from Transgenic Mice Containing Megabase Human Immunoglobulin Loci Are Opsonic and Protective against Fatal Pseudomonas Sepsis, 10.1128/iai.69.4.2223-2229.2001
  22. Horn M. P., Zuercher A. W., Imboden M. A., Rudolf M. P., Lazar H., Wu H., Hoiby N., Fas S. C., Lang A. B., Preclinical In Vitro and In Vivo Characterization of the Fully Human Monoclonal IgM Antibody KBPA101 Specific for Pseudomonas aeruginosa Serotype IATS-O11, 10.1128/aac.01142-09
  23. Secher T., Fauconnier L., Szade A., Rutschi O., Fas S. C., Ryffel B., Rudolf M. P., Anti-Pseudomonas aeruginosa serotype O11 LPS immunoglobulin M monoclonal antibody panobacumab (KBPA101) confers protection in a murine model of acute lung infection, 10.1093/jac/dkr038
  24. Hostacká A, Majtán V (1997) Serotyping and virulence factors of Pseudomonas aeruginosa clinical isolates. Acta Microbiol Immunol Hung 44(2):141–146
  25. Faure K., Shimabukuro D., Ajayi T., Allmond L. R., Sawa T., Wiener-Kronish J. P., O-Antigen Serotypes and Type III Secretory Toxins in Clinical Isolates of Pseudomonas aeruginosa, 10.1128/jcm.41.5.2158-2160.2003
  26. Fonseca António Pedro, Correia Petra, Sousa João Carlos, Tenreiro Rogério, Association patterns ofPseudomonas aeruginosaclinical isolates as revealed by virulence traits, antibiotic resistance, serotype and genotype : Pseudomonas aeruginosaassociation patterns revealed by virulence, 10.1111/j.1574-695x.2007.00328.x
  27. Le Berre Rozenn, Nguyen Sophie, Nowak Emmanuel, Kipnis Eric, Pierre Maud, Quenee Lauriane, Ader Florence, Lancel Steve, Courcol René, Guery Benoît P., Faure Karine, Relative contribution of three main virulence factors in Pseudomonas aeruginosa pneumonia* : , 10.1097/ccm.0b013e31821e899f
  28. Lu Qin, Eggimann Philippe, Luyt Charles-Edouard, Wolff Michel, Tamm Michael, François Bruno, Mercier Emmanuelle, Garbino Jorge, Laterre Pierre-François, Koch Holger, Gafner Verena, Rudolf Michael P, Mus Erkan, Perez Antonio, Lazar Hedvika, Chastre Jean, Rouby Jean-Jacques, Pseudomonas aeruginosa serotypes in nosocomial pneumonia: prevalence and clinical outcomes, 10.1186/cc13697
  29. Lu Q., Rouby J.-J., Laterre P.-F., Eggimann P., Dugard A., Giamarellos-Bourboulis E. J., Mercier E., Garbino J., Luyt C.-E., Chastre J., Georgescu-Kyburz V., Rudolf M. P., Gafner V., Lazar H., Koch H., Perez A., Kramer S. D., Tamm M., Pharmacokinetics and safety of panobacumab: specific adjunctive immunotherapy in critical patients with nosocomial Pseudomonas aeruginosa O11 pneumonia, 10.1093/jac/dkr046
  30. KNAUS WILLIAM A., DRAPER ELIZABETH A., WAGNER DOUGLAS P., ZIMMERMAN JACK E., APACHE II : A severity of disease classification system, 10.1097/00003246-198510000-00009
  31. Vincent J. -L., Moreno R., Takala J., Willatts S., De Mendonça A., Bruining H., Reinhart C. K., Suter P. M., Thijs L. G., The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure : On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine (see contributors to the project in the appendix), 10.1007/bf01709751
  32. Luna Carlos M., Blanzaco Daniel, Niederman Michael S., Matarucco Walter, Baredes Natalio C., Desmery Pablo, Palizas Fernando, Menga Guillermo, Rios Fernando, Apezteguia Carlos, Resolution of ventilator-associated pneumonia: Prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome* : , 10.1097/01.ccm.0000055380.86458.1e